GenMark Diagnostics to Present at the 32nd Annual J.P. Morgan Healthcare Conference
January 07 2014 - 1:20PM
Business Wire
GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of
automated, multiplex molecular diagnostic testing systems, will
present at the 32nd Annual J.P. Morgan Healthcare Conference to be
held at the Westin St. Francis Hotel in San Francisco, CA on
Wednesday, January 15, 2014. The presentation will be delivered by
Hany Massarany, President and Chief Executive Officer, and is
scheduled to begin at 9:30 a.m. Pacific Time (12:30 p.m. Eastern
Time). The live webcast and audio archive of the presentation will
be available at http://ir.genmarkdx.com/events.cfm. A replay of the
webcast will be available on the company’s website for
approximately 90 days.
ABOUT GENMARK
GenMark Diagnostics is a leading provider of automated,
multiplex molecular diagnostic testing systems that detect and
measure DNA and RNA targets to diagnose disease and optimize
patient treatment. Utilizing GenMark's proprietary eSensor®
detection technology, GenMark's eSensor® XT-8 system is designed to
support a broad range of molecular diagnostic tests with a compact,
easy-to-use workstation and self-contained, disposable test
cartridges. GenMark currently markets four tests that are FDA
cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory
Virus Panel, Thrombophilia Risk Test, and Warfarin Sensitivity
Test. A number of other tests, including HCV Genotyping, 2C19
Genotyping, and 3A4/3A5 Genotyping are available for research use
only. For more information, visit www.genmarkdx.com.
GenMark Diagnostics, Inc.Hany MassaranyPresident, Chief
Executive Officer760-448-4358
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Mar 2024 to Apr 2024
GenMark Diagnostics (NASDAQ:GNMK)
Historical Stock Chart
From Apr 2023 to Apr 2024